Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA).

被引：0
|
作者：
Makawita, Shalini
Gibbs, Jerry M.
McFadden, Dustin R.
Porter, Caroline
Shaw, Amanda Rosewell
Robertson, Catherine
Woods, Mae Louise
Wang, Tao
Grilley, Bambi J.
Heslop, Helen E.
Brenner, Malcolm K.
Suzuki, Masataka
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Houston Methodist Hosp, Houston, TX USA
[3] Baylor Coll Med, Cell & Gene Therapy, Houston, TX USA
[4] Texas Childrens Hosp, Houston, TX USA
[5] Baylor Coll Med, Div Diabet Endocrinol & Metab, Houston, TX USA
[6] Baylor Coll Med, Div Pediat, Houston, TX USA
[7] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA
[8] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2679
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Enhanced antitumor effects of oncolytic reovirus and trastuzumab combination therapy in human HER2-positive gastric cancer
    Kataoka, H.
    Hamano, S.
    Aoyama, M.
    Mori, Y.
    Tanaka, M.
    Hayashi, N.
    Kubota, E.
    Johnston, R.
    Joh, T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S183 - S183
  • [42] First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer
    Araki, Kazuhiro
    Fukada, Ippei
    Yanagi, Hiroyo
    Kobayashi, Kokoro
    Shibayama, Tomoko
    Horii, Rie
    Takahashi, Shunji
    Akiyama, Futoshi
    Ohno, Shinji
    Ito, Yoshinori
    BREAST, 2017, 35 : 78 - 84
  • [43] Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer
    Jiang, M.
    Chai, Y.
    Liu, J.
    He, M.
    Zhang, M.
    Zhou, S.
    Xu, B.
    Li, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S353 - S353
  • [44] HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
    Ahmed, Nabil
    Salsman, Vita S.
    Kew, Yvonne
    Shaffer, Donald
    Powell, Suzanne
    Zhang, Yi J.
    Grossman, Robert G.
    Heslop, Helen E.
    Gottschalk, Stephen
    CLINICAL CANCER RESEARCH, 2010, 16 (02) : 474 - 485
  • [45] Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
    Ferrario, Cristiano
    Christofides, Anna
    Joy, Anil Abraham
    Laing, Kara
    Gelmon, Karen
    Brezden-Masley, Christine
    CURRENT ONCOLOGY, 2022, 29 (04) : 2720 - 2734
  • [46] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Aoki, Masahiko
    Iwasa, Satoru
    Boku, Narikazu
    GASTRIC CANCER, 2021, 24 (03) : 567 - 576
  • [47] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Masahiko Aoki
    Satoru Iwasa
    Narikazu Boku
    Gastric Cancer, 2021, 24 : 567 - 576
  • [48] Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
    Ock, Chan-Young
    Lee, Keun-Wook
    Kim, Jin Won
    Kim, Jin-Soo
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Han, Sae-Won
    Im, Seock-Ah
    Kim, Tae-You
    Kim, Woo Ho
    Bang, Yung-Jue
    Oh, Do-Youn
    CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2520 - 2529
  • [49] FIRST-LINE TREATMENT IN HER2-POSITIVE ADVANCED OR METASTATIC GASTRIC CANCER
    Yamaguchi, K.
    Ooki, A.
    Yamada, T.
    Hara, H.
    Asayama, M.
    Tada, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
  • [50] MyPathway HER2 basket study: Pertuzumab (P) plus trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.
    Meric-Bernstam, Funda
    Hainsworth, John
    Bose, Ron
    Burris, Howard A., III
    Friedman, Claire Frances
    Kurzrock, Razelle
    Swanton, Charles
    Wang, Yong
    Levy, Jonathan
    Schulze, Katja
    Price, Richard
    Patel, Arisha
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345